NCT06771596 2025-01-13
CC11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT06039891 2023-09-15
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05606263 2023-05-26
GCR-05
Xi'an Jiaotong University
Phase 2 Unknown
NCT03413579 2021-08-25
CIMAHOPE
El Kendi Pharmaceuticals Manufacturing Company
Phase 3 Completed
NCT03469531 2018-08-13
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Zhujiang Hospital
Phase 2 Unknown
NCT02705612 2016-03-10
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
Air Force Military Medical University, China
Phase 2 Unknown
NCT02095119 2015-04-14
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
National Institute of Cancerología
Phase 1/2 Completed